Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

被引：1
|
作者：
Palazzo, A. [1 ]
Toss, A. [2 ]
Graffeo, R. [3 ]
Fontana, A. [4 ]
Lambertini, M. [5 ]
Pantaleo, F. [4 ]
Perachino, M. [6 ]
Nerone, M. [7 ]
Bianco, N. [8 ]
Vici, P. [9 ]
de Marchis, L. [10 ]
Staropoli, N. [11 ]
Rinaldi, L. [12 ]
Lai, A. [13 ]
Spinelli, G. P. [14 ]
Di Monte, E. [15 ]
Giotta, F. [12 ]
Gennari, A. [16 ]
Cortesi, L. [17 ]
Bria, E. [18 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Comprehens Canc Ctr, Rome, Italy
[2] Azienda Osped Univ Policlin Modena, Dept Oncol & Haematol, Modena, Italy
[3] EOC Osped Reg Lugano Sede Italiano, IOSI, Lugano, Switzerland
[4] AOU Pisana Stabilimento Santa Chiara, Med Oncol, Pisa, Italy
[5] IRCCS AOU San Martino, IST Ist Nazl Ric Cancro, Clin Oncol Med, Genoa, Italy
[6] IRCCS Osped Policlin San Martino, Clin Oncol Dept, Genoa, Italy
[7] EOC Osped Reg Bellinzona & Valli, Ist Oncol Svizzera Italiana IOSI, Reparto Oncol, Bellinzona, Switzerland
[8] IEO Ist Europeo Oncol, Med Senol Dept, Milan, MB, Italy
[9] IRCCS Regina Elena Natl Canc Inst, Phase 4 Clin Study Unit, Rome, Italy
[10] Univ Roma la Sapienza, Fac Med, Radiol Oncol Pathol, Latina, Italy
[11] UMG Univ Magna Graecia Catanzaro, Med Clin & Sperimentale, Catanzaro, Italy
[12] IRCCS, Ist Tumori Bari Giovanni Paolo II, Oncol Inst, Bari, Italy
[13] Mater Olbia Hosp, Dept Oncol, Olbia, Italy
[14] Oncol Univ ASL Aprilia, Dist ASL Latina 1, Aprilia, Italy
[15] Fdn Policlin Univ Agostino Gemelli, IRCCS, Ctr Comprehens Canc, Med Oncol Dept,Unit Med Oncol, Rome, Italy
[16] AOU Maggiore Carita Novara, Dept Translat Med, Novara, Italy
[17] Azienda Osped Univ Policlin Modena, SC Oncol Med, SS Genet Oncol, Modena, Italy
[18] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Translat Med & Surg, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [1] Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
    Schettini, Francesco
    Palleschi, Michela
    Mannozzi, Francesca
    Braso-Maristany, Fara
    Cecconetto, Lorenzo
    Galvan, Patricia
    Mariotti, Marita
    Ferrari, Alessia
    Scarpi, Emanuela
    Miserocchi, Anna
    Nanni, Oriana
    Sanfeliu, Esther
    Prat, Aleix
    Rocca, Andrea
    De Giorgi, Ugo
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions
    Pla, H.
    Recalde Penabad, S.
    Vinas Villaro, G.
    Margeli Vila, M.
    Obadia Gil, V. L.
    Cirauqui Cirauqui, B.
    Del Barco Berron, S.
    J. Gil, M.
    Quiroga Garcia, V.
    Teruel-Garcia, I.
    Pernas Simon, S.
    Stradella, A.
    Esteve Gomez, A. M.
    Felip, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S660 - S660
  • [3] Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
    Phuong, Lisa
    Patel, Janki
    Baka, Nadia
    Goldman, Jessica
    Lyudmer, Michael
    Shamir, Stephanie
    Deng, Junwen
    Soto, Alvaro Alvarez
    Anampa Mesias, Jesus Del Santo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC)
    Wander, Seth A.
    Cohen, Ofir
    Gong, Xueqian
    Johnson, Gabriela N.
    Buendia-Buendia, Jorge
    Lloyd, Maxwell
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Helvie, Karla
    Kowalski, Kailey
    Nayar, Utthara
    Parsons, Stephen
    Martinez, Ricardo
    Litchfield, Lacey
    Ye, Xiang
    Yu, Chun Ping
    Jansen, Valerie
    Garraway, Levi A.
    Winer, Eric P.
    Tolaney, Sara M.
    Lin, Nancy U.
    Buchanan, Sean
    Wagle, Nikhil
    CANCER RESEARCH, 2020, 80 (04)
  • [5] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [6] A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i)
    Mainor, Candace Bavette
    Barrows, Elizabeth Dominic
    Wang, Hongkun
    Lynce, Filipa
    Ashai, Nadia
    Collins, Julie Marie
    Swanson, Nicole
    Castle, Julie
    Novielli, Antonella
    Slingerland, Joyce
    Isaacs, Claudine
    Pohlmann, Paula R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
    von Arx, C.
    Calabrese, A.
    Martinelli, C.
    Di Lauro, V.
    Grimaldi, V.
    Pensabene, M.
    Caputo, R.
    Cerillo, I.
    Cianniello, D.
    Buono, G.
    Verrazzo, A.
    Pacilio, C.
    Di Rella, F.
    Nuzzo, F.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [8] A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
    Kalinsky, Kevin
    Accordino, Melissa Kate
    Chiuzan, Codruta
    Mundi, Prabhjot Singh
    Trivedi, Meghna S.
    Novik, Yelena
    Tiersten, Amy
    Raptis, George
    Baer, Lea N.
    Oh, Sun Young
    Zelnak, Amelia Bruce
    Wisinski, Kari Braun
    Andreopoulou, Eleni
    Gradishar, William John
    Stringer-Reasor, Erica
    Reid, Sonya A.
    O'Dea, Anne
    O'Regan, Ruth
    Crew, Katherine D.
    Hershman, Dawn L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [9] Whole exome sequencing (WES) in hormone-receptor positive (HR plus ) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
    Wander, Seth Andrew
    Cohen, Ofir
    Johnson, Gabriela N.
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Nayar, Utthara
    Helvie, Karla
    Marini, Lori
    Freeman, Samuel
    Getz, Gad
    Garraway, Levi A.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
    Litton, Jennifer Keating
    Beck, Joseph Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Blum, Joanne Lorraine
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael A.
    Yuan, Yuan
    Abbattista, Antonello
    Noonan, Kay
    Chakrabarti, Jayeta
    Czibere, Akos
    Symmans, William Fraser
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345